About Chembio Diagnostics: Chembio is a leading point-of-care diagnostics company focused on creating fast actionable tests to diagnose diseases quickly and accurately, including STIs and COVID-19, enabling expedited treatment. Chembio tests are easy to use and provide results in approximately 15 minutes using some of the smallest sample sizes of fingertip blood, nasal swabs and other sample types. Chembio recently received FDA CLIA Waiver for the first rapid point-of-care combination test for HIV & Syphilis. Coupled with Chembio’s extensive scientific expertise, its novel DPP® technology offers broad market applications beyond infectious disease. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com. About the DPP Rapid Test Platform: Chembio’s proprietary DPP® technology platform provides high-quality, rapid diagnostic results in 15 to 20 minutes using a small drop of blood from the fingertip or alternative samples. Through advanced multiplexing, the DPP platform can detect up to eight, distinct test results from a single patient sample, delivering greater clinical value than other rapid tests. For certain applications, Chembio’s easy-to-use, highly portable, battery-operated DPP Micro Reader optical analyzer then reports accurate results in approximately 15 seconds, making it well-suited for decentralized testing where real-time results enable patients to be clinically assessed while they are still on-site. Objective results produced by the DPP Micro Reader reduce the possibility of the types of human error that can be experienced in the visual interpretations required by many rapid tests.
